Enhancing Gpx1 Palmitoylation to Inhibit Angiogenesis by Targeting PPT1
The significance of protein S-palmitoylation in angiogenesis has been largely overlooked, leaving various aspects unexplored. Recent identification of Gpx1 as a palmitoylated protein has generated interest in exploring its potential involvement in novel ...
Shaobo Su, Azim Patar, Eryan Kong
exaly +6 more sources
The Interactome of Palmitoyl-Protein Thioesterase 1 (PPT1) Affects Neuronal Morphology and Function [PDF]
Palmitoyl-protein thioesterase 1 (PPT1) is a depalmitoylation enzyme that is mutated in cases of neuronal ceroid lipofuscinosis (NCL). The hallmarks of the disease include progressive neurodegeneration and blindness, as well as seizures.
Orly Reiner +2 more
exaly +9 more sources
An over-expression system for characterizing
Background The infantile onset form of Neuronal Ceroid Lipofuscinoses (INCL) is the earliest and most severe form of NCL, with neurological symptoms that reflect massive neurodegeneration in the CNS and retina.
Korey Christopher A +3 more
core +6 more sources
Quantitative analysis of PPT1 interactome in human neuroblastoma cells. [PDF]
Mutations in the CLN1 gene that encodes Palmitoyl protein thioesterase 1 (PPT1) or CLN1, cause Infantile NCL (INCL, MIM#256730). PPT1 removes long fatty acid chains such as palmitate from modified cysteine residues of proteins. The data shown here result
Gingras, Anne-Claude +14 more
core +8 more sources
Background Hepatocellular carcinoma (HCC) is a malignancy with limited treatment options and poor prognosis. Macrophages are enriched in the HCC microenvironment and have a significant impact on disease progression and therapy efficacy.
Yong Yi +11 more
core +5 more sources
Seizures in PPT1 Knock-In Mice Are Associated With Inflammatory Activation of Microglia
Infantile neuronal ceroid lipofuscinosis (INCL), the most severe form of neuronal ceroid lipofuscinoses, is caused by mutations in the lysosomal enzyme palmitoyl protein thioesterase 1 (PPT1).
Shiyong Peng, Mingyong Wang, Tong Jia
exaly +4 more sources
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma [PDF]
Abstract Background Adaptive resistance and side effects of sorafenib treatment result in unsatisfied survival of patients with hepatocellular carcinoma (HCC). Palmitoyl-protein thioesterase 1 (PPT1) plays a critical role in progression of various cancers.
Jianjun Xu +10 more
openaire +3 more sources
PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma [PDF]
New strategies are needed to enhance the efficacy of anti–programmed cell death protein antibody (anti–PD-1 Ab) in cancer. Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target of chloroquine derivatives like ...
Jennifer J. Lee +19 more
core +5 more sources
PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer [PDF]
Clinical trials repurposing lysosomotropic chloroquine (CQ) derivatives as autophagy inhibitors in cancer demonstrate encouraging results, but the underlying mechanism of action remains unknown.
Estela Noguera-Ortega +2 more
exaly +4 more sources
AAV-Delivered PPT1 Provides Long-Term Neurological Benefits in CLN1 Mice and Achieves Therapeutic Levels in Sheep Brain [PDF]
CLN1 disease is a fatal neurodegenerative condition caused by deficiency in Palmitoyl-Protein Thioesterase 1 (PPT1), for which no disease-modifying therapy exists.
Suhail Alam, Maria G Biferi
exaly +4 more sources

